These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 18176616)

  • 21. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.
    Tsukimoto I; Tawa A; Horibe K; Tabuchi K; Kigasawa H; Tsuchida M; Yabe H; Nakayama H; Kudo K; Kobayashi R; Hamamoto K; Imaizumi M; Morimoto A; Tsuchiya S; Hanada R
    J Clin Oncol; 2009 Aug; 27(24):4007-13. PubMed ID: 19620491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low incidence of secondary neoplasia after autotransplantation for lymphoproliferative disease: the role of pre-transplant therapy.
    Laurenti L; Tarnani M; Chiusolo P; La Torre G; Garzia M; Zollino M; Zini G; Balducci M; Leone G; Sica S
    Clin Transplant; 2008; 22(2):191-9. PubMed ID: 18339139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation.
    Boehm A; Sperr WR; Leitner G; Worel N; Oehler L; Jaeger E; Mitterbauer M; Haas OA; Valent P; Kalhs P; Rabitsch W
    Eur J Clin Invest; 2008 Dec; 38(12):945-52. PubMed ID: 19021720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies.
    Díez-Campelo M; Pérez-Simón JA; Pérez J; Alcoceba M; Richtmon J; Vidriales B; San Miguel J
    Am J Hematol; 2009 Mar; 84(3):149-52. PubMed ID: 19123459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia.
    Rubnitz JE; Razzouk BI; Lensing S; Pounds S; Pui CH; Ribeiro RC
    Cancer; 2007 Jan; 109(1):157-63. PubMed ID: 17133407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fludarabine, treosulfan and etoposide sensitivity and the outcome of hematopoietic stem cell transplantation in childhood acute myeloid leukemia.
    Styczynski J; Toporski J; Wysocki M; Debski R; Chybicka A; Boruczkowski D; Wachowiak J; Wojcik B; Kowalczyk J; Gil L; Balwierz W; Matysiak M; Krawczuk-Rybak M; Balcerska A; Sonta-Jakimczyk D
    Anticancer Res; 2007; 27(3B):1547-51. PubMed ID: 17595774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
    Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
    Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
    Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell support: experience by the Italian Association of Pediatric Hematology and Oncology.
    Spreafico F; Bisogno G; Collini P; Jenkner A; Gandola L; D'Angelo P; Casazza G; Piva L; Luksch R; Perotti D; Pession A; Fagioli F; Dallorso S
    Pediatr Blood Cancer; 2008 Jul; 51(1):23-8. PubMed ID: 18293386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stem cell transplant in the treatment of childhood biphenotypic acute leukemia.
    Park JA; Ghim TT; Bae Kw; Im HJ; Jang SS; Park CJ; Chi HS; Seo JJ
    Pediatr Blood Cancer; 2009 Sep; 53(3):444-52. PubMed ID: 19489056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical problems in the treatment of myeloid leukemia in childhood].
    Kiyotani C; Kiyokawa N; Mori T
    Nihon Rinsho; 2009 Oct; 67(10):1991-6. PubMed ID: 19860203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute myeloid leukaemia in children.
    Langmuir PB; Aplenc R; Lange BJ
    Best Pract Res Clin Haematol; 2001 Mar; 14(1):77-93. PubMed ID: 11355925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
    Lekakis L; de Lima M
    Expert Rev Anticancer Ther; 2008 May; 8(5):785-98. PubMed ID: 18471050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia.
    Zwaan CM; Kaspers GJ
    Br J Haematol; 2004 Nov; 127(3):264-79. PubMed ID: 15491285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
    Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Quigley J; Chen YH; Mahmud N; Hurter E; Beri R; Rondelli D
    Bone Marrow Transplant; 2008 Jun; 41(11):935-40. PubMed ID: 18264144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.
    Kornblit B; Masmas T; Madsen HO; Ryder LP; Svejgaard A; Jakobsen B; Sengeløv H; Olesen G; Heilmann C; Dickmeiss E; Petersen SL; Vindeløv L
    Bone Marrow Transplant; 2008 May; 41(10):851-9. PubMed ID: 18246114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia.
    Meshinchi S; Arceci RJ
    Oncologist; 2007 Mar; 12(3):341-55. PubMed ID: 17405900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pediatric acute myeloid leukemia: towards high-quality cure of all patients.
    Kaspers GJ; Zwaan CM
    Haematologica; 2007 Nov; 92(11):1519-32. PubMed ID: 18024401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
    Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
    Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current European practice in pediatric myeloablative conditioning.
    Vettenranta K;
    Bone Marrow Transplant; 2008 Jun; 41 Suppl 2():S14-7. PubMed ID: 18545236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.